Milestone Scientific Secures Key Patent Approvals in the U.S. and Europe
Milestone Scientific Inc. (NYSE: MLSS) has received multiple Notices of Allowance for key patent applications in the U.S. and Europe. These patents cover the company's next-generation Dynamic Pressure Sensing® (DPS) technology for real-time pressure-sensing guidance in manual injection systems and the new CompuPulse System for identifying pulsatile pressure waveforms.
The DPS technology enables fluid-pressure analysis to compare pressure signals, alert pressure thresholds, and display pressure graphs, enhancing the safety and precision of manual injections. The CompuPulse System improves the reliability and safety of drug delivery using manual syringes.
CEO Arjan Haverhals stated that these patent approvals significantly broaden the company's intellectual property foundation and reinforce its leadership in the computerized injection market, while opening new avenues for their technology in diverse markets and applications.
Milestone Scientific Inc. (NYSE: MLSS) ha ricevuto numerosi Avvisi di Concessione per importanti domande di brevetto negli Stati Uniti e in Europa. Questi brevetti coprono la tecnologia di Dynamic Pressure Sensing® (DPS) di nuova generazione dell'azienda, per la guida della pressione in tempo reale nei sistemi di iniezione manuale, e il nuovo CompuPulse System per l'identificazione delle forme d'onda della pressione pulsatile.
La tecnologia DPS consente l'analisi della pressione dei fluidi per confrontare i segnali di pressione, avvisare le soglie di pressione e visualizzare grafici della pressione, migliorando la sicurezza e la precisione delle iniezioni manuali. Il CompuPulse System aumenta l'affidabilità e la sicurezza della somministrazione di farmaci utilizzando siringhe manuali.
Il CEO Arjan Haverhals ha dichiarato che queste approvazioni di brevetto ampliano significativamente la base di proprietà intellettuale dell'azienda e rafforzano la sua leadership nel mercato delle iniezioni computerizzate, aprendo al contempo nuove strade per la loro tecnologia in mercati e applicazioni diverse.
Milestone Scientific Inc. (NYSE: MLSS) ha recibido múltiples Avisos de Concesión para solicitudes de patente clave en EE. UU. y Europa. Estas patentes cubren la tecnología de Dynamic Pressure Sensing® (DPS) de próxima generación de la empresa, para la guía de presión en tiempo real en sistemas de inyección manual, y el nuevo CompuPulse System para identificar las formas de onda de presión pulsátil.
La tecnología DPS permite el análisis de presión de fluidos para comparar señales de presión, alertar sobre umbrales de presión y mostrar gráficos de presión, mejorando la seguridad y la precisión de las inyecciones manuales. El CompuPulse System mejora la fiabilidad y seguridad de la administración de medicamentos mediante jeringas manuales.
El CEO Arjan Haverhals declaró que estas aprobaciones de patentes amplían significativamente la base de propiedad intelectual de la empresa y refuerzan su liderazgo en el mercado de inyecciones computarizadas, al tiempo que abren nuevas oportunidades para su tecnología en diversos mercados y aplicaciones.
Milestone Scientific Inc. (NYSE: MLSS)는 미국과 유럽에서 주요 특허 출원에 대해 여러 차례 허가 통지를 받았습니다. 이러한 특허는 회사의 차세대 Dynamic Pressure Sensing® (DPS) 기술을 포함하고 있으며, 수동 주사 시스템에서 실시간 압력 감지 안내와 CompuPulse System을 위한 맥동 압력 파형 식별 기능을 제공합니다.
DPS 기술은 유체 압력 분석을 통해 압력 신호를 비교하고, 압력 역행에 경고하며, 압력 그래프를 표시하여 수동 주사의 안전성과 정밀성을 향상시킵니다. CompuPulse System은 수동 주사기를 사용하는 약물 전달의 신뢰성과 안전성을 개선합니다.
CEO Arjan Haverhals는 이러한 특허 승인이 회사의 지적 재산 기반을 상당히 확장하고, 컴퓨터화된 주사 시장에서의 리더십을 강화하며, 다양한 시장과 응용 분야에서 기술의 새로운 경로를 열어준다고 언급했습니다.
Milestone Scientific Inc. (NYSE: MLSS) a reçu plusieurs Avis de Concession pour des demandes de brevet clés aux États-Unis et en Europe. Ces brevets couvrent la technologie de Dynamic Pressure Sensing® (DPS) de nouvelle génération de l'entreprise, pour un guidage de pression en temps réel dans les systèmes d'injection manuels et le nouveau CompuPulse System pour l'identification des formes d'onde de pression pulsatile.
La technologie DPS permet l'analyse de la pression des fluides pour comparer les signaux de pression, avertir des seuils de pression et afficher des graphiques de pression, améliorant ainsi la sécurité et la précision des injections manuelles. Le CompuPulse System améliore la fiabilité et la sécurité de l'administration des médicaments à l'aide de seringues manuelles.
Le PDG Arjan Haverhals a déclaré que ces approbations de brevet élargissent considérablement la base de propriété intellectuelle de l'entreprise et renforcent sa position de leader sur le marché des injections informatisées, tout en ouvrant de nouvelles voies pour leur technologie dans divers marchés et applications.
Milestone Scientific Inc. (NYSE: MLSS) hat mehrere Genehmigungsbescheide für wichtige Patentanmeldungen in den USA und Europa erhalten. Diese Patente decken die nächste Generation der Dynamic Pressure Sensing® (DPS) Technologie des Unternehmens ab, die eine Echtzeit-Druckmessführung in manuellen Injektionssystemen ermöglicht, sowie das neue CompuPulse System, das zur Identifizierung pulsierender Druckwellenformen dient.
Die DPS-Technologie ermöglicht die Druckanalyse von Flüssigkeiten, um Drucksignale zu vergleichen, Druckschwellen zu warnen und Druckgrafiken anzuzeigen, was die Sicherheit und Präzision manueller Injektionen verbessert. Das CompuPulse System erhöht die Zuverlässigkeit und Sicherheit der Medikamentenverabreichung mit manuellen Spritzen.
CEO Arjan Haverhals erklärte, dass diese Patenterteilungen das geistige Eigentum des Unternehmens erheblich erweitern und seine Führungsposition im computergestützten Injektionsmarkt stärken, während sie gleichzeitig neue Möglichkeiten für ihre Technologie in verschiedenen Märkten und Anwendungen eröffnen.
- Receipt of multiple Notices of Allowance for key patent applications in the U.S. and Europe
- Expansion of intellectual property portfolio for next-generation injection technologies
- Potential for new market opportunities and applications
- None.
The patent approvals for Milestone Scientific's Dynamic Pressure Sensing® (DPS) technology and CompuPulse System represent significant advancements in injection safety and precision. These innovations address critical challenges in medical procedures, potentially reducing complications and improving patient outcomes.
The DPS technology's ability to provide real-time pressure-sensing guidance in manual injection systems is particularly noteworthy. This could revolutionize various medical procedures, from local anesthesia to more complex interventions. By enabling fluid-pressure analysis, comparing pressure signals and alerting to pressure thresholds, the technology could significantly enhance the accuracy of needle and catheter placement.
The CompuPulse System's capability to identify pulsatile pressure waveforms adds another layer of safety and precision to drug delivery. This could be especially valuable in scenarios where accurate identification of specific anatomical structures is crucial, such as in regional anesthesia or vascular access procedures.
From a market perspective, these patents strengthen Milestone Scientific's position in the computerized injection market. The company's expanded intellectual property portfolio could lead to new product developments, potential licensing opportunities and increased market share. However, it's important to note that patent approvals don't guarantee market success. The company will need to effectively commercialize these technologies and navigate regulatory hurdles to realize their full potential.
Overall, these patent approvals represent a positive development for Milestone Scientific, potentially opening doors to new markets and applications while reinforcing their existing product offerings.
The receipt of multiple Notices of Allowance (NOA) in both the U.S. and Europe significantly bolsters Milestone Scientific's intellectual property portfolio. This development is particularly important in the medical device industry, where robust patent protection is important for maintaining competitive advantage and driving innovation.
The patents cover two key technologies:
- Dynamic Pressure Sensing® (DPS) technology for real-time pressure-sensing guidance in manual injection systems
- CompuPulse System for identifying pulsatile pressure waveforms in various applications
The breadth of these patents, covering both the U.S. and European markets, provides Milestone Scientific with a strong foundation for market expansion and potential licensing opportunities. The company now has increased leverage to protect its innovations from competitors and potentially generate additional revenue streams through licensing agreements.
However, it's important to note that patent protection is just one aspect of a successful IP strategy. The company will need to continue innovating and developing new technologies to maintain its competitive edge. Additionally, they should be prepared to defend these patents if challenged, which can be a costly and time-consuming process.
From an investor's perspective, this strengthened IP position could make Milestone Scientific a more attractive target for partnerships or acquisitions in the medical device industry. It also provides a degree of reassurance regarding the company's ability to protect its market share and potentially expand into new areas.
Overall, these patent approvals represent a significant milestone for the company, paving the way for future growth and innovation in the computerized injection market.
ROSELAND, N.J., July 30, 2024 (GLOBE NEWSWIRE) -- Milestone Scientific Inc. (NYSE: MLSS), a leading developer of computerized drug delivery instruments that provide painless and precise injections, today announced receipt of multiple Notices of Allowance (NOA) for essential patent applications in both the U.S. and Europe.
One NOA was granted by the U.S. Patent and Trademark Office and one NOA was granted by the European Patent Office for a new patent titled “Device and Method for Needle/Catheter Location Utilizing Correlation Analysis.” These patent applications cover Milestone Scientific’s next-generation Dynamic Pressure Sensing® (DPS) technology for real-time pressure-sensing guidance in manual injection systems. The innovative DPS technology enables fluid-pressure analysis to compare pressure signals, alert pressure thresholds, and display pressure graphs, in order to ensure accurate positioning of needles and catheters, as well as enhance the safety and precision of manual injections.
Additionally, Milestone Scientific received an NOA from the European Patent Office for a patent application titled “Device and Method for Identification of a Target Region.” This patent application relates to the new CompuPulse System, which identifies pulsatile pressure waveforms in various applications, thereby improving the reliability and safety of drug delivery using manual syringes. A corresponding patent for this technology has already been granted in the United States.
Arjan Haverhals, CEO and President of Milestone Scientific, stated, “These Notices of Allowance in the United States and Europe significantly broaden the intellectual property foundation of our injection and drug delivery systems. These advancements not only reinforce our leadership in the computerized injection market but also open new avenues for our technology in diverse markets and applications.”
About Milestone Scientific Inc.
Milestone Scientific Inc. (MLSS) is a technology-focused medical research and development company that patents, designs and develops innovative injection technologies and instruments for medical and dental applications. Milestone Scientific’s computer-controlled systems are designed to make injections precise and efficient, as well as increase overall patient comfort and safety. The Company’s proprietary DPS Dynamic Pressure Sensing Technology® provides a platform to advance the development of next-generation devices, regulating flow rate and monitoring pressure from the tip of the needle, through platform extensions involving subcutaneous drug delivery of local anesthetic. To learn more, view the MLSS brand video or visit milestonescientific.com.
Safe Harbor Statement
This press release contains forward-looking statements regarding the timing and financial impact of Milestone's ability to implement its business plan, expected revenues, timing of regulatory approvals and future success. These statements involve a number of risks and uncertainties and are based on assumptions involving judgments with respect to future economic, competitive and market conditions, future business decisions and regulatory developments, all of which are difficult or impossible to predict accurately and many of which are beyond Milestone's control. Some of the important factors that could cause actual results to differ materially from those indicated by the forward-looking statements are general economic conditions, failure to achieve expected revenue growth, changes in our operating expenses, adverse patent rulings, FDA or legal developments, competitive pressures, changes in customer and market requirements and standards, and the risk factors detailed from time to time in Milestone's periodic filings with the Securities and Exchange Commission, including without limitation, Milestone's Annual Report for the year ended December 31, 2023. The forward-looking statements in this press release are based upon management's reasonable belief as of the date hereof. Milestone undertakes no obligation to revise or update publicly any forward-looking statements for any reason.
Contact:
Crescendo Communications, LLC
Email: mlss@crescendo-ir.com
Tel: 212-671-1020
FAQ
What patents did Milestone Scientific (MLSS) receive approval for in July 2024?
How does Milestone Scientific's DPS technology enhance manual injections?
What is the purpose of Milestone Scientific's CompuPulse System?
How do these patent approvals impact Milestone Scientific's market position?
